Your fact-checks will appear here
Austrian flag carrier airline
Ultrasensitive PSA (uPSA) assays detect PSA at levels below 0.1 ng/mL — in some labs down to ~0.001–0.006 ng/mL — and so can identify biochemical recurrence earlier than standard assays, which typical...
Penis pumps (vacuum erection devices, VEDs) are widely described as a generally safe, non‑drug option with lower complication rates than invasive treatments and can be used with ED medications; common...
Three major prostate‑cancer guideline bodies—NCCN, AUA, and EAU—agree on the central role of serial PSA after radical prostatectomy but diverge on measurement sensitivity, timing of intervention, imag...
Independent urology experts evaluate treatments primarily through peer-reviewed reviews, specialty journals, and society guidelines; major review outlets such as Nature Reviews Urology and Current Uro...
Clinical guidelines for erectile dysfunction in people with diabetes include vacuum erection devices (penis pumps) as an option alongside PDE5 inhibitors, injections, and surgery; the ADA’s 2025 Stand...
Guidelines permit, but do not mandate, use of ultrasensitive PSA (usPSA) after radical prostatectomy: the AUA/ASTRO/SUO panel says clinicians may obtain usPSA in patients at high risk of recurrence wh...
Ultrasensitive PSA (uPSA) assays detect levels well below conventional thresholds (commonly <0.1 ng/mL and in some assays down to ~0.003–0.001 ng/mL), and studies show lower uPSA nadirs and early rise...
Guidelines recommend considering salvage radiation therapy (SRT) earlier rather than later because multiple large datasets show better outcomes when SRT is given at lower PSA — with common thresholds ...
Vacuum therapy (vacuum erection devices, VEDs, or vacuum constriction devices) is a non‑invasive, generally safe treatment for erectile dysfunction that works by drawing blood into the penis; reported...
Urologists assess anticoagulated patients for procedures by weighing thrombotic risk, bleeding risk of the planned intervention, pharmacology of the agent, and patient factors such as renal function a...
Major urology societies (EAU, AUA, CUA) publish rigorous clinical-guideline frameworks and endorse high standards for study design, reporting and quality, but the publicly available guideline portfoli...
Current guideline-based care treats erectile dysfunction (ED) as a condition requiring both risk‑factor modification and shared decision‑making: lifestyle changes and management of comorbid disease ar...
American and European urology authorities position vacuum erection devices (VEDs) as established, non‑pharmacologic options that must be discussed with men who have erectile dysfunction, but neither s...
Biochemical recurrence that is suspected or imaged without a concomitant rise in standard PSA levels is unusual but documented, and management balances early salvage intent against risks of overtreatm...
No single, universally accepted PSA cutoff mandates salvage radiotherapy (sRT) after radical prostatectomy, but contemporary evidence and guidelines converge on “the earlier the better” — many studies...
After radical prostatectomy PSA usually falls to very low or undetectable levels within weeks to a few months; major guideline thresholds and recent studies disagree on exact cutoffs and timing. Sourc...
Clinical trials and reviews show low‑intensity shockwave therapy (Li‑SWT/ESWT) has the strongest randomized‑trial and meta‑analysis signal for modest improvement in erectile function, while evidence f...
After radical prostatectomy, biochemical recurrence (BCR) is commonly defined as a rising PSA with thresholds historically at ≥0.2 ng/mL (post‑prostatectomy) but contemporary practice uses ultrasensit...
Randomized trials and large observational studies find that early (immediate or "early salvage") radiotherapy after biochemical recurrence generally lowers the risk of later metastasis versus delayed ...
FactBasedUrology is not directly described in the available reporting; current urology coverage in 2025 instead highlights major conferences, regulatory actions, device and drug approvals, and awarene...